Stock 1541 IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:04 19/06/2024 pm IST 		5-day change 1st Jan Change
14.26 HKD +0.71% Intraday chart for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. -2.46% -52.31%
03/06 ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug MT
30/05 ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug
MT
ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares
MT
ImmuneOnco Biopharmaceuticals Inc. Approves the Appointment of Guan Mei as Executive Director
CI
Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China
MT
Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS)
CI
ImmuneOnco Obtains Chinese Nod for Phase III Trials of Anti-Cancer Medication
MT
ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01
CI
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases
MT
ImmuneOnco Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Immuneonco Biopharmaceuticals CFO Resigns
MT
Immuneonco Biopharmaceuticals Inc. Announces Board and Executive Changes
CI
ImmuneOnco Begins Phase II Clinical Trial of Anti-Tumor Drug
MT
ImmuneOnco Biopharmaceuticals Inc. Announces First Patient Dosed in the Phase II Clinical Trial of IMM2510 for the Treatment of Refractory or Relapsed Alveolar Soft Part Sarcoma
CI
ImmuneOnco Biopharmaceuticals Gets US FDA's Orphan-Drug Designation for Leukemia Drug Combination
MT
ImmuneOnco Biopharmaceuticals Gets Nod to Trial Cancer Drug
MT
ImmuneOnco Biopharmaceuticals Inc. Receives an Investigational New Drug Approval from the National Medical Products Administration of the People's Republic of China
CI
ImmuneOnco to Present Results of Anti-Cancer Drug Studies at American Convention
MT
China Grants Investigational New Drug Approval to ImmuneOnco's Cancer Treatment; Shares Fall 4%
MT
ImmuneOnco Biopharmaceuticals Inc. Obtains an Investigational New Drug Approval for IMM47 for the Treatment of Solid Tumors from the National Medical Products Administration of the People's Republic of China
CI
ImmuneOnco to Raise Near HK$17 Million from Over-Allotment of Shares
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1541 Stock
  4. News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.